Abstract
(vii) With products for the treatment of respiratory and cardiac disorders, the barbiturate ingredient may depress respiration in patients with asthma or bronchitis in whom respiration is already impaired and in patients with chronic respiratory disease. (viii) (In other cases) there is insufficient evidence that the barbiturate ingredient contributes to the action of the non barbiturate component. (7) The guidelines are concerned with the marketing of these drugs in the UK for medical use of oral barbiturates in clinical practice. They are complementary to the measures being taken at the present time by the Home Office, under Schedule 2 to the Misuse of Drugs Act 1971, which is intended to prevent the misuse of this group of drugs. Data-sheet guidelines for use of oral barbiturate preparations (excluding phenobarbitone) Indications. Severe intractable insomnia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
